Institute of Pathology and Forensic Medicine, Military Medical Academy, Crnotravska 17, 11000, Belgrade, Serbia.
Institute for the Application of Nuclear Energy - INEP, University of Belgrade, Belgrade, Serbia.
Head Neck Pathol. 2022 Mar;16(1):200-212. doi: 10.1007/s12105-021-01337-1. Epub 2021 Jun 2.
Peripheral localisation of papillary thyroid microcarcinoma (PTMC), in comparison with intraparenchymal PTMC (i-PTMC) is related to some clinicopathological features related with biological aggressiveness, including lymph node metastasis (LNM). The expression of PD-L1 in tumour cell has been associated with increased tumour survival, progression, and potentially an aggressive clinical course. This study evaluates the relation between clinicopathological features of PTMC, including tumour localisation, with PD-L1 immunoexpression. The study included 99 patients with the histological diagnosis of PTMC (≥ 5 mm). PD-L1 protein expression was assessed by immunohistochemistry. PTMCs were divided into the four following groups: G1- peripherally localised PTMC (p-PTMC) with PD-L1 expression; G2-p-PTMC without PD-L1 expression; G3-i-PTMC with PD-L1 expression and G4-i-PTMC without PD-L1 expression. G1 was the most frequent (n = 46; 46.5%), followed by G4 (n = 25; 25.3%) and similar distribution of G3 (n = 15; 15.2%) and G2 (n = 13; 13.1%). In comparison with other groups, G1 was significantly associated with classical morphology, invasive growth, lymphatic invasion (LI), vascular invasion (VI), psammoma bodies, intratumoral fibrosis, PD-L1 positive tumour-infiltrating lymphocytes, and multinuclear giant cells (MGCs). G4 more commonly exhibited follicular morphology, expansive/circumscribed growth, and absence of the following: intratumoural fibrosis, LI, VI, psammoma bodies, PD-L1 positive tumour-infiltrating lymphocytes, and MGCs. LNMs were significantly more frequent in G1 in comparison with the other groups (p = 0.000). In conclusion, morphology and tumour microenvironment of p-PTMC with PD-L1 expression is different from i-PTMC without PD-L1 expression. The differences between these two groups of PTMC include clinicopathological features related with biological aggressiveness such as the occurrence of LNM.
甲状腺乳头状微小癌(PTMC)的外周定位与实质内 PTMC(i-PTMC)相比,与一些与生物学侵袭性相关的临床病理特征有关,包括淋巴结转移(LNM)。肿瘤细胞中 PD-L1 的表达与肿瘤存活、进展和潜在的侵袭性临床病程有关。本研究评估了 PTMC 的临床病理特征,包括肿瘤定位与 PD-L1 免疫表达之间的关系。该研究纳入了 99 例组织学诊断为 PTMC(≥5mm)的患者。通过免疫组织化学评估 PD-L1 蛋白表达。PTMC 分为以下 4 组:G1-外周定位的 PTMC(p-PTMC)伴 PD-L1 表达;G2-p-PTMC 无 PD-L1 表达;G3-i-PTMC 伴 PD-L1 表达和 G4-i-PTMC 无 PD-L1 表达。G1 最常见(n=46;46.5%),其次是 G4(n=25;25.3%),G3(n=15;15.2%)和 G2(n=13;13.1%)的分布相似。与其他组相比,G1 与经典形态、侵袭性生长、淋巴血管侵犯(LI)、血管侵犯(VI)、砂粒体、肿瘤内纤维化、PD-L1 阳性肿瘤浸润淋巴细胞和多核巨细胞(MGCs)显著相关。G4 更常见的是滤泡形态、扩张/局限性生长,缺乏以下特征:肿瘤内纤维化、LI、VI、砂粒体、PD-L1 阳性肿瘤浸润淋巴细胞和 MGCs。与其他组相比,G1 中 LNMs 的发生率显著更高(p=0.000)。总之,PD-L1 阳性的 p-PTMC 的形态和肿瘤微环境与无 PD-L1 表达的 i-PTMC 不同。这两组 PTMC 之间的差异包括与生物学侵袭性相关的临床病理特征,如 LNM 的发生。